𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rituximab in the management of refractory myasthenia gravis

✍ Scribed by Nazlee Zebardast; Huned S. Patwa; Steven P. Novella; Jonathan M. Goldstein

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
136 KB
Volume
41
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunoglobulin treatment in refractory m
Immunoglobulin treatment in refractory myasthenia gravis
✍ Anat Achiron; Yoram Barak; Shmuel Miron; Ida Sarova-Pinhas 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 2 views

Failure to induce and maintain remission in severe exacerbations of myasthenia gravis (MG), despite optimal care, is a common problem. We evaluated the efficacy and safety of high-dose intravenous immunoglobulin (IVIg) therapy in an open-label study of 10 patients with severe generalized myasthenia

Clinical evaluation and management of my
Clinical evaluation and management of myasthenia gravis
✍ John C. Keesey 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 254 KB

## Abstract Myasthenia gravis (MG) is a syndrome of fluctuating skeletal muscle weakness that worsens with use and improves with rest. Eye, facial, oropharyngeal, axial, and limb muscles may be involved in varying combinations and degrees of severity. Its etiology is heterogeneous, divided initiall

Successful treatment of MuSK antibody–po
Successful treatment of MuSK antibody–positive myasthenia gravis with rituximab
✍ Berit Hain; Karin Jordan; Marcus Deschauer; Stephan Zierz 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract We report on a 56‐year‐old woman with muscle‐specific receptor tyrosine kinase (MuSK) antibody–positive myasthenia with predominant bulbar symptoms and respiratory insufficiency. Conventional immunosuppression (prednisolone, azathioprine, mycophenolate mofetil) could not maintain the cl

High-dose cyclophosphamide in refractory
High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies
✍ Peter T. Lin; Beth A. Martin; Ann B. Weinacker; Yuen T. So 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

## Abstract We describe a 48‐year‐old woman with seronegative myasthenia gravis (MG) and high‐titer of anti‐MuSK antibody. She had severe bulbar and respiratory weakness with minimal limb weakness for 2 years. Her disease responded poorly to all the conventional immunosuppressive regimens. Treatmen

Response of myasthenia gravis to rituxim
Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma
✍ Ajeet Gajra; Neerja Vajpayee; Sara J. Grethlein 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB 👁 2 views

## Abstract Myasthenia gravis is a B‐cell‐mediated autoimmune neuromuscular disorder characterized by weakness and fatigability of skeletal muscles. The underlying defect is an autoantibody‐mediated attack on the acetylcholine receptors (AchRs) at the neuromuscular junction. Rituximab is a genetica